एटोनोजेस्ट्रेल और एथिनिल एस्ट्राडियोल और मिटापिवैट का इंटरैक्शन

Sensitive CYP3A substrates including hormonal contraceptives: Avoid concomitant use with substrates that have narrow therapeutic index.

Avoid concomitant use with hormonal contraceptives except for intrauterine systems containing levonorgestrel.

Co-administration of AQVESME will decrease systemic concentrations of drugs that are sensitive CYP3A substrates, including hormonal contraceptives (e.g., ethinyl estradiol) [see Clinical Pharmacology (12.3) ] .

Counsel patients to use a back-up or alternative method of contraception when enzyme inducers are used with CHCs.

Counsel women to use an alternative non-hormonal method of contraception or a back-up method when enzyme inducers are used with Etonogestrel/Ethinyl Estradiol Vaginal Ring, and to continue back-up non-hormonal contraception for 28 days after discontinuing the enzyme inducer to ensure contraceptive reliability.